Facing stiff competition for its lead cancer product, MorphoSys AG is turning its attention to two Phase 3 trials that, if successful, could give it significant added momentum on the US market. This comes as the German company adjusts its US sales forecast for the product, Monjuvi (tafasitamab), a second-line treatment for diffuse large B cell lymphoma (DLBCL). Sales for 2022 are now expected to be $90 million instead of the previously forecast $90 million to $110 million.
